We demonstrated high-resolution tandem mass spectrometry with an ultra-high-performance liquid chromatography for characterization and comparison between biologics and biosimilar of infliximab at an advanced level. Comparing the N- and O-glycopeptides profiles, a total of 49 and 54 glycopeptides was identified for each product of the biologics and biosimilar, respectively. We also discovered one novel N-glycosylation site at the light chain from both biopharmaceuticals and one novel O-glycopeptide at the heavy chain from only biosimilar. Site-specific glycopeptide analysis process will be a robust and useful technique for evaluating therapeutic mAbs and complex glycoprotein products.
[doi:10.25345/C5154DT0S]
[dataset license: CC0 1.0 Universal (CC0 1.0)]
Keywords: glycoproteome ; infliximab ; monoclonal antibody ; biopharmaceuticals
|
Principal Investigators: (in alphabetical order) |
Heeyoun Hwang, Korea Basic Science Institute, Rep of Korea |
| Submitting User: | tilldawn |
| Number of Files: | |
| Total Size: | |
| Spectra: | |
| Subscribers: | |
| Owner | Reanalyses | |
|---|---|---|
| Experimental Design | ||
|
Conditions:
|
||
|
Biological Replicates:
|
||
|
Technical Replicates:
|
||
| Identification Results | ||
|
Proteins (Human, Remapped):
|
||
|
Proteins (Reported):
|
||
|
Peptides:
|
||
|
Variant Peptides:
|
||
|
PSMs:
|
||
| Quantification Results | ||
|
Differential Proteins:
|
||
|
Quantified Proteins:
|
||
| Browse Dataset Files | |
|
FTP Download Link (click to copy):
|